Axsome Therapeutics

Auvelity COM depression; AXS-07 NDA migraine; AXS-14 Clin3 fibromyalgia; AXS-05 Clin3 Alzheimer's agitation, Clin2 smoking cessation; AXS-12 Clin3 cataplexy in narcolepsy (ODD); solriamfetol Clin2 ADHD

Axsome Therapeutics is developing therapies that target the central nervous system (CNS) to help patients with depression, migraines, narcolepsy, fibromyalgia and smoking addiction. Axsome is designing therapeutic options with novel mechanisms of action to transform the current approach to treat CNS disorders. This approach involves internally-derived candidates and in-licensed candidates with development and commercialization. Axsome’s pipeline is already diversified with 4 lead compounds in Phase 1,2 & 3 clinical trials targeting conditions that currently have limited treatment options. One compound, AXS-05, is an oral NMDA receptor antagonist to treat depression and Alzheimer’s disease agitation.